ZA201200716B - Modified factor ix polypeptides and uses thereof - Google Patents

Modified factor ix polypeptides and uses thereof

Info

Publication number
ZA201200716B
ZA201200716B ZA2012/00716A ZA201200716A ZA201200716B ZA 201200716 B ZA201200716 B ZA 201200716B ZA 2012/00716 A ZA2012/00716 A ZA 2012/00716A ZA 201200716 A ZA201200716 A ZA 201200716A ZA 201200716 B ZA201200716 B ZA 201200716B
Authority
ZA
South Africa
Prior art keywords
polypeptides
modified factor
factor
modified
Prior art date
Application number
ZA2012/00716A
Other languages
English (en)
Inventor
Alan Brooks
Chandra Patel
Xiaoqiao Jiang
Uwe Gritzan
Heiner Apeler
Jun Wang
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201200716(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of ZA201200716B publication Critical patent/ZA201200716B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2012/00716A 2009-07-31 2012-01-30 Modified factor ix polypeptides and uses thereof ZA201200716B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
ZA201200716B true ZA201200716B (en) 2013-07-31

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00716A ZA201200716B (en) 2009-07-31 2012-01-30 Modified factor ix polypeptides and uses thereof

Country Status (21)

Country Link
US (1) US20120164130A1 (cg-RX-API-DMAC10.html)
EP (1) EP2461821A4 (cg-RX-API-DMAC10.html)
JP (1) JP2013500726A (cg-RX-API-DMAC10.html)
KR (1) KR20120060209A (cg-RX-API-DMAC10.html)
CN (1) CN102573890A (cg-RX-API-DMAC10.html)
AU (1) AU2010278721A1 (cg-RX-API-DMAC10.html)
BR (1) BR112012002072A2 (cg-RX-API-DMAC10.html)
CA (1) CA2769258A1 (cg-RX-API-DMAC10.html)
CL (1) CL2012000238A1 (cg-RX-API-DMAC10.html)
CR (1) CR20120052A (cg-RX-API-DMAC10.html)
CU (3) CU20120018A7 (cg-RX-API-DMAC10.html)
DO (1) DOP2012000030A (cg-RX-API-DMAC10.html)
EA (1) EA201290069A1 (cg-RX-API-DMAC10.html)
EC (1) ECSP12011637A (cg-RX-API-DMAC10.html)
GT (1) GT201200023A (cg-RX-API-DMAC10.html)
IN (1) IN2012DN00908A (cg-RX-API-DMAC10.html)
MX (1) MX2012001346A (cg-RX-API-DMAC10.html)
PE (1) PE20121643A1 (cg-RX-API-DMAC10.html)
SG (1) SG178119A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011014890A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201200716B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655639T3 (es) 2006-12-15 2018-02-21 Baxalta GmbH Conjugado de factor VIIa - ácido (poli)siálico que tiene una semivida in vivo prolongada
CA2737094C (en) 2008-09-15 2018-02-20 Paolo Simioni Factor ix polypeptide mutant, its uses and a method for its production
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
BR112013001611B1 (pt) * 2010-07-30 2022-05-10 Takeda Pharmaceutical Company Limited Método para conjugar um polímero solúvel em água a uma fração de carboidrato oxidado de uma proteína terapêutica, proteína terapêutica modificada, método para formar uma ligação oxima entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo amino-óxi ativo emétodo para formar uma ligação hidrazona entre uma fração de carboidrato oxidado em uma proteína terapêutica e um polímero solúvel em água ativado contendo um grupo hidrazida ativo
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
RU2617764C2 (ru) * 2011-12-19 2017-04-26 Дилафор Аб Неантикоагулянтные гликозаминогликаны, содержащие повторяющиеся дисахаридные звенья, и их медицинское применение
BR112015011462A2 (pt) * 2012-11-20 2017-09-26 Univ North Carolina Chapel Hill processos e composições para proteínas fator ix modificadas
PL2970424T3 (pl) * 2013-03-13 2017-11-30 Eli Lilly And Company Zmodyfikowane polipeptydy leptyny psowatych
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
EA201890423A1 (ru) 2015-08-03 2018-07-31 Биовератив Терапьютикс Инк. Слитые белки фактора ix, способы их получения и применения
EP4566666A3 (en) 2016-07-27 2025-09-17 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor ix function
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
JP7578590B2 (ja) 2018-10-18 2024-11-06 インテリア セラピューティクス，インコーポレーテッド 第ｉｘ因子を発現するための組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005055950A2 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
WO2007149406A2 (en) * 2006-06-19 2007-12-27 Nautilus Technology Llc Modified coagulation factor ix polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
DOP2012000030A (es) 2012-02-29
CU20120018A7 (es) 2012-06-21
WO2011014890A1 (en) 2011-02-03
CL2012000238A1 (es) 2012-10-05
PE20121643A1 (es) 2012-11-25
ECSP12011637A (es) 2012-02-29
MX2012001346A (es) 2012-02-17
CU20130057A7 (es) 2013-06-28
SG178119A1 (en) 2012-03-29
GT201200023A (es) 2014-01-27
EP2461821A1 (en) 2012-06-13
BR112012002072A2 (pt) 2016-11-08
JP2013500726A (ja) 2013-01-10
CR20120052A (es) 2012-06-04
CU20130058A7 (es) 2013-06-28
US20120164130A1 (en) 2012-06-28
EP2461821A4 (en) 2013-07-03
IN2012DN00908A (cg-RX-API-DMAC10.html) 2015-04-03
CA2769258A1 (en) 2011-02-03
CN102573890A (zh) 2012-07-11
KR20120060209A (ko) 2012-06-11
EA201290069A1 (ru) 2012-07-30
AU2010278721A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
ZA201200716B (en) Modified factor ix polypeptides and uses thereof
IL208718A0 (en) Modified factor ix polypeptides and uses thereof
ZA201303134B (en) Modified factor ix polypeptides and uses thereof
GB0916576D0 (en) Polypeptides and uses thereof
GB0916578D0 (en) Polypeptides and uses thereof
IL225740A0 (en) Adapted factor vii polypeptides and uses thereof
SI2483292T1 (sl) Variantni polipeptidi lovd in njihove uporabe
SG10201506443TA (en) Modified relaxin polypeptides and their uses
IL217551A0 (en) Bifunctional stapled polypeptides and uses thereof
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
IL221278A0 (en) Chlorotoxin polypeptides and conjugates and uses thereof
IL210265A0 (en) Modified bovine g - csf polypeptides and their uses
IL207096A0 (en) Modified leptin polypeptides and their uses
PL2464656T3 (pl) Nowy peptyd i jego zastosowanie
GB0905790D0 (en) Novel polypeptides and use thereof
ZA201007681B (en) Cd4-related polypeptides and methods of use
GB0909792D0 (en) Composition and uses thereof
GB0800698D0 (en) F2 polypeptides and usesthereof
GB0800701D0 (en) F10 Polypeptides and uses thereof
GB0800700D0 (en) F9 polypeptides and uses thereof
GB0800502D0 (en) Peptides and their uses
GB0816561D0 (en) Peptides and uses thereof
GB0910620D0 (en) Agents and uses thereof